YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Screening of Antineoplastic Immunomodulator from Herbal Medicines

천연물로부터 항암면역증강물질 탐색연구

  • Song, Jie-Young (Laboratory of Immunology, Korea cancer center Hospital KAERI) ;
  • Yang, Hyun-Ok (Department of Traditional Medicines, Asan Medical Center) ;
  • Pyo, Suhk-Neung (College of Pharmacy, Sungkyunkwan University) ;
  • Park, Sin-Young (Laboratory of Immunology, Korea cancer center Hospital KAERI) ;
  • Kim, Ki-Hwan (Laboratory of Immunology, Korea cancer center Hospital KAERI) ;
  • Son, Eun-Hwa (College of Pharmacy, Sungkyunkwan University) ;
  • Kang, Nam-Sung (College of Pharmacy, Sungkyunkwan University) ;
  • Yun, Yeon-Sook (Laboratory of Immunology, Korea cancer center Hospital KAERI)
  • Published : 1998.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Currently, cancer is the primary cause of death and 50% of cancer patients are incurable by surgery, radiotherapy and chemotherapy. Therefore, immunotherpy is interested as the fourth remedy. Biological response modifier (BRM), such as organometallic compounds, glycoproteins, polysaccharides and other natural products. Is the one which can enhance the immune response against cancer cell. To develop new BRM from natural sources, we investigated 63 species Korean traditional medicines by observing the mitogenic activity to splenocytes, generation of activated killer cells and activation of macrophages. Finally, we selected 9 species including Angelicae gigantis Radix, Mori Cortex Radicis, Arisaematis Tuber, Salviae Radix, Cnidii Rhizoma, Ligusti Fructus, Pasoraliae Semen, Loranthi Ramulus, Ginseng Radix. Bioassay-guided fractionation and purification is undergoing.

Keywords

References

  1. M. Engl. J. Med. v.313 Observations on the systemic administraion of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer Rosenberg, S.;M. Lotze;L. Muul;S. Leitman;A. Chang;S. Ettinghausen;Y. Matury;J. Skibber;E. Shilon;J. Vetto;C. Seipp;C.Smpson;C. Reichert
  2. J. Immunol. v.135 The antitumor efficacy of lymphokine-actovated killer cells and recombinant interleukin-2 in vivo Mule, J.J.;S. Shu, S.Rosenberg
  3. J. Immunol. v.138 Long-term growth of lymphokine-activated killer (LAK) cells : role of anti-CD3, β-IL-1, interferon-γ and β Ochoa, A.C.;G. Gromo;B.J. Alter;P.M. Sondel;F.Ⅱ. Bach
  4. J. Immunol. v.138 Lymphokine-activated killer (LAK). Ⅱ. Delineation of distinct murine LAK-precursor subpopulation Ballas, Z.K.;W.Rasmussen;J.K. Van Otegham
  5. J. Immunol. v.137 Murine lymphokine-activated killer (LAK) cells:phenoytpic characterization of the precursors and effector cells Tang, J.C.;J.J. Mule;S. Rosenberg
  6. J. Exp. Med. v.155 Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes Geimm, E.A.;A. Mazumder, Ⅱ;Z. Zhang;S.A. Rosenberg
  7. J. Biol. Resp. Mod. v.1 Biological Response Modifiers Program Oldham, R.K.
  8. Behring Inst. Mitt. v.74 Tumor models to investigate the therapeutic efficiency of immunomodulators Talmadge, E.;Lenz, B.F.;Collins, M.S.;Uithoven, K.A.;Schneider, M.A.;Adam-s, J.S.;Pearson, J.W.;Agee, W.J.;Fox, R.E.;Oldham, R.K.
  9. Behring Inst, Mitt. v.74 The NCI preclinical screen of biolog-ical response modifiers Talmadge, J.E.;Fidler, I.J.;Oldham, R.K.
  10. Phytochemistry v.11 Immunologically active polysaccharide-s of A-contopanax senticosus Fang, J.N.;Proksch, A.;Wagner, H.
  11. Drug Exptl. Clin. Res. v.12 Phase Ⅰ trials of biological response modifiers Smalley, R.V.;Oldham, R.K.
  12. Cancer Treatment Resports v.70 The preclinical screening laboratory: Eval-uation of immunomodulatory and therapeutic properties of biological response modifiers Talmadge, J.E.;Herberman, R.B.
  13. J. Immunology v.134 Augmentation of mouse natural killer cell activity by LS 2616: a new immunomodulator Kalland, T.;Alm, G.;Stalhandske, T.
  14. Mol. Biother. v.1 The ideal biological response modifier Wimer, B.M.
  15. Jpn. J. Cancer Res. v.70 Comparative study on antitumor effect of cell-wall skeleton of Mycovacterium bovis BCG and Nocardia rubra. with reference to T-cell dependency and independency Yanagawa, E.;Yasumoto, K.;Ohta, M;Nomoto, K.;Azuma, I.;Yamamura, Y.
  16. Int. J. Immunopharmac. v.3 In Vitro augmentation of natural killing activity by OK-432 Atsushi Uchida, Michael Micksche
  17. Cancer v.66 Evaluation of the worth of Corynebacterium parvum in conjuction with chemotherpy as adjuvant treatment for primary breast cancer Fisher, B.;Brown, A.;Wolmark, N.;Fisher, E.R.;Redmond, C.;Wickerham, D.L.;Margolese R.;Dimitrov. N. Pilch Y.;Glass A.;Sutherland C.;Foster R.
  18. Proc. Natl. Acad. Sci. v.85 Induction of macrophage antitumor activity by a cetylated low density lipoprotein containing lipophilic tripeptide Shaw, J.M.;Futch, W.S.;Schook, L.B.
  19. Nature v.232 Endotoxin and double-stranded RNA render macrophages cytotoxic Alexander, P.;Evans, R.
  20. Nature v.330 A new immunomodulating compound (AS101) with potential therapeutic application B. Sredri;R.R. Caspi;A. Klein;Y. Kalechman;Y. Danziger;M. BenYa'akov;T. Tamari;F. Shalit;M. Albeck
  21. In progres-s in cancer research and therpy v.20 Lymphokines and thymic hormones Goldstein, A.L.;Ahirigos, M.A.
  22. Intl. J. Immunopharmacol. v.6 T-cell mediated vascular dilation and genorrhage induced by antitumor polysaccharide Maeda, Y.Y.;Watanabe, S.T.Chihara, G.;Rokutanda, M.
  23. J. Natl. Med. Assoc. v.81 a new antineoplastic immunomodula-tor Mohla, S.;Humphries M.J.;White, S.L.;Matsumoto, K.;Newton, S.A.;Sampson, C.C.;Bowen, D.;Olden, K.;Swansonine
  24. J. Natl. Cancer Institute v.80 Natural products as antitumor agents:direct versus indirect mechanisms of activity of flavonoids Robert H. Wiltrout;Ronald L. Hornung
  25. Prog. Med. Virol. v.18 On the role of mononuclear phagocytes in immunity Allison, A.C.
  26. Bact. Rev. v.28 Aspects of the pathogenesis of virus diseases Mims, C.A.
  27. Microbiolol. Rev. v.43 Role of macrophage in natural resistance to virus infections Mogensen, S.C.
  28. J. Infect. Dis. v.135 Therapeutic efficacy of liposome-encapsulated robavirin and muramyl tripeptide in experimental infection with influenza and herpes simplex virus Gangemi D.;Nachtigal M.;Barnhart D.;Krech L.;Jani P.J.
  29. J. Infect. Dis. v.135 Immunonodulation of host resistance to experimental viral infections in mice Glasgow, L.A.;Fischbach, J.;Bryant, S.M.;Kern, E.R.
  30. Infect. Immun. v.16 Protection against herpes simplex infection in mice by Corynevacterium parvum Kirchner, H.;Hirt, H.M.;Munk, K.
  31. Ann. Rev. Microbiol. v.43 The genomes of the human herpesviruses: Contents, relationship-s and evolution McGeoch, D.J.
  32. Proc. Soc. Exp. Biol. Med. v.154 Immunomodulator-induced resista-nce against herpes simplex virus Morahan, P.S.;Kern, E.R.;Glasgow, L.A.
  33. Nature v.268 Macrophages isolated from regression: Molon-ey sarcoma are more cytotoxic than those recovered from progressing sarcomas Russell, S.W.;McIntosh, A.T.
  34. Cell. Immunol. v.53 The murine bone marrow macrophage. a sensitive indicator cell for murine inhibitory factor and a new method for their harvest Klimetzek, V.;Remold, H.G.
  35. J. Leukoc. Biol. v.50 Poly Ⅰ:C-induced anti-herp-es simplex virus type Ⅰ activity in inflammatory macrophages is mediated by induction of interferon-β Pyo, S.;Gangmi, J.D.;Ghaffar A.;Mayer E.P.